Operator

Good morning, and welcome to the Xeris Biopharma Q1 '26 Earnings Conference Call. [Operator Instructions]

I will now pass the call over to Allison Wey for opening remarks. Please go ahead.

Allison Wey
Senior Vice President of Investor Relations & Corporate Communications

Thank you, Sarah. Good morning, everyone, and welcome to Xeris' First Quarter Financial Results Conference Call. Earlier this morning, we issued a press release detailing our first quarter 2026 financial and operating results. This press release can be found on our website.

Joining me today is John Shannon, our Chief Executive Officer; and Steve Pieper, our Chief Financial Officer. Following our prepared remarks, we will open the call for your questions.

Before we begin, I'd like to remind you that today's discussion will include forward-looking statements regarding Xeris' future expectations, plans, strategies, objectives and financial performance. These forward-looking statements are based on management's current assumptions and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. For a discussion of these risks and uncertainties, please refer to the risk factors described in our filings with the SEC.

Any forward-looking statements made on this call speak only as of today's date. And except as required by law, the company undertakes